Short communication · 26 Dec 2025
Research articlePublished 18 Dec 2020
No Clear Benefit to the use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019: A Retrospective Cohort Study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Coronavirus disease 2019 (COVID-19) is becoming an increasing global health issue which has spread across the globe. We aimed to study the effect of corticosteroids in the treatment of adult inpatients with COVID-19. A retrospective cohort of 115 consecutive adult COVID-19 patients admitted to Hubei NO.3 People’s Hospital of Jianghan University between Jan 18, 2020, and Feb 28, 2020 was analysed to study the effectiveness of corticosteroid. They were categorized according to whether or not corticosteroid therapy was given, and compared in terms of demographic characteristics, clinical features, laboratory indicators and clinical outcomes. The primary endpoint was defined as either mortality or intensive care unit (ICU) admission. Known adverse prognostic factors were used as covariates in multiple logistic regressions to adjust for their confounding effects on outcomes. Among 115 patients, 73 patients (63.5%) received corticosteroid. The levels of age, C-reactive protein, D-dimer and albumin were similar in both groups. The corticosteroid group had more adverse outcomes (32.9% vs. 11.9%) and statistically significant differences were observed (p=0.013). In multivariate analysis, corticosteroid treatment was associated with a 2.155-fold increase in risk of either mortality or ICU admission, although not statistically significant. No evidence suggests that adult patients with COVID-19 will benefit from corticosteroids in this study, and they might be more likely to be harmed with such treatment.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunogenetics: Open Access.
Opinion · 25 Dec 2025
Tapasin: The Molecular Gatekeeper of Antigen Presentation
Opinion · 24 Dec 2025
Molecular Chaperones: The Cellular Guardians of Protein Folding
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunogenetics: Open Access
- SubjectImmunology & Microbiology
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Liu Yongming”
